Kemira invests in emulsion polymer manufacturing in Alabama

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
23
Kemira invests in emulsion polymer manufacturing in Alabama USA

Kemira Oyj Press Release February 8, 2019 at 8.45 am (CET+1)

Kemira invests in emulsion polymer manufacturing in Alabama USA

Kemira has announced a two-year investment of around EUR 60 million to significantly increase production of high molecular weight emulsion polymers at its manufacturing site in Mobile, Alabama. These polymers are primarily used in the oil and gas industry, where Kemira is a leading supplier. Additionally, this expansion allows Kemira to modernize into bio-based acrylamide capabilities at the Mobile site.

"For Kemira this investment is an important step towards the growth objectives outlined in our strategy. It also secures our position as a leading global polymer producer and demonstrates our continued commitment to the oil and gas industry." said Pedro Materan , SVP, Oil & Gas.

Construction at Mobile is scheduled to begin in the first quarter of 2019 with full commercial operation in early 2021. The project will also create 20 new full-time positions at the site which currently employs about 60 people.

For more information, please contact

Kemira Oyj Pedro Materan, SVP, Global Oil & Gas, Industry & Water Tel. +1 832 941 0061

Olli Turunen, Vice President, Investor Relations Tel. +358 40 552 8907

Kemira is a global chemicals company serving customers in water intensive industries. We provide best suited products and expertise to improve our customers' product quality, process and resource efficiency. Our focus is on pulp & paper, oil & gas and water treatment. In 2018, Kemira had annual revenue of around EUR 2.6 billion and 4,915 employees. Kemira shares are listed on the Nasdaq Helsinki Ltd. www.kemira.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading